Vaccine Adjuvants - Market Insights, Competitive Landscape, and Market Forecast - 2030

Vaccine Adjuvants - Market Insights, Competitive Landscape, and Market Forecast - 2030

Vaccine Adjuvants Market By Product Type (Oil-In-Water Emulsion, Aluminium Salts, Liposomes, Saponin-Based Adjuvants, And Others), Disease Type (Infectious Diseases, Cancer, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady CAGR forecast till 2030 owing to the growing prevalence of infectious and cancer diseases and growing unmet vaccine market needs for certain diseases

The global vaccine adjuvants market is estimated to grow at a CAGR of 12.91% during the forecast period from 2024 to 2030. The demand for vaccine adjuvants is primarily driven by the increasing prevalence of infectious and cancerous diseases. In addition, the growing need for vaccines for certain diseases, increasing focus on immunization, and expanding vaccination programs worldwide are some of the other key factors contributing to the growth of the vaccine adjuvants market. This growth is expected to continue during the forecast period from 2024 to 2030.

Vaccine Adjuvants Market Dynamics:

As per the 2023 data from the World Health Organization, over 1 million cases of sexually transmitted infections (STIs) are contracted daily worldwide, with the majority displaying no symptoms. Annually, an estimated 374 million new infections are reported, and more than 500 million individuals aged 15–49 are believed to carry genital herpes simplex virus (HSV) infections. Additionally, human papillomavirus (HPV) infection, as indicated by the same source, is linked to over 311,000 deaths from cervical cancer annually.

The data highlights the importance of comprehensive sexual health education, accessible healthcare services for screening and treatment, as well as preventive measures such as vaccination against HPV, STIs, and HSV. Thus, resulting in the positive growth of the vaccine adjuvants market.

The increasing demand for vaccines to combat various diseases presents significant opportunities for the vaccine adjuvants market to expand. For instance, data from the WHO's Global Tuberculosis Report 2023 underscores the need for enhanced vaccination efforts, particularly in regions with high tuberculosis prevalence such as Southeast Asia, Africa, and the Western Pacific. As infectious diseases continue to pose significant health challenges worldwide, the demand for vaccines is expected to rise, thereby driving growth in the vaccine adjuvants market.

Furthermore, advancements in vaccine adjuvants, such as the introduction of new products by companies, are contributing to market expansion. For instance, Evonik's launch of PhytoSquene in December 2022 represents a notable innovation. PhytoSquene, derived from plants, offers a safe and animal-free source of squalene for use in vaccines and medical applications. Such developments cater to the increasing demand for sustainable solutions in the market, further propelling market growth projections.

However, the various side effects and high toxicity of adjuvants, and the high research & development cost of developing a new adjuvant, may act as factors that are expected to limit the growth of the vaccine adjuvants market.

Vaccine Adjuvants Market Segment Analysis:

Vaccine Adjuvants Market by Product Type (Oil-In-Water Emulsion, Aluminium Salts, Liposomes, Saponin-Based Adjuvants, and Others), Disease Type (Infectious Diseases, Cancer, And Others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the Vaccine Adjuvants market, the oil-in-water emulsion category is estimated to amass a significant revenue share in the Vaccine Adjuvants Market in 2023. This can be attributed to the various advantages and applications provided by oil-in-water emulsions such as they have enhanced immunogenicity, which has been shown to enhance the immune response to vaccines significantly. They can stimulate innate and adaptive immune responses, improving protection against infectious diseases. Additionally, this is primarily attributed to the increasing prevalence of communicable diseases, driving the utilization of oil-in-water emulsion adjuvants in vaccines and subsequently fostering the growth of this segment.

Further, oil-in-water emulsions allow for the reduction of antigen doses while maintaining or even enhancing the immune response. This dose-sparing effect is beneficial in increasing vaccine availability, especially during vaccine shortages or in resource-limited settings. Therefore, the various advantages and applications provided by the oil-in-water emulsion category will contribute to the growth of the segment, thereby driving the growth of the overall vaccine adjuvants market during the forecast period.

North America Is Expected To Dominate The Overall Vaccine Adjuvants Market:

North America is expected to account for the highest proportion of the Vaccine Adjuvants Market in 2023, out of all regions. The North America vaccine adjuvants market is experiencing growth due to several factors. Firstly, the region has a strong healthcare infrastructure and robust research and development capabilities, fostering innovation in vaccine adjuvant technologies. Additionally, rising incidences of infectious diseases and the threat of potential pandemics, such as influenza outbreaks or emerging pathogens, have prompted increased investment in vaccine development and adjuvant research. Moreover, government initiatives aimed at expanding vaccination programs and improving public health preparedness further drive market growth. Overall, these factors converge to fuel the growth of the vaccine adjuvants market in North America. For instance, in January 2021, the United States Department of Health and Human Services (HHS) launched the HPV VAX NOW campaign to increase human papillomavirus (HPV) vaccination rates among young adults ages 18-26.

Also, in August 2022, the Government of Canada published the Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2022-2023, which provides updated recommendations regarding the use of seasonal influenza vaccines in Canada. Hence, such an initiative from the government is expected to drive market growth.

Additionally, various strategies such as product approval, launches, agreements, and developments help the market to grow over the study period. For instance, in November 2022, GSK plc reported that the US FDA accepted a Biologics License Application (BLA) and granted priority review for its respiratory syncytial virus (RSV) older adult vaccine candidate. The US FDA grants priority review to applications for vaccines that, if approved, would offer significant improvements in the safety or effectiveness of the treatment or prevention of serious conditions when compared to standard applications.

Thus, the rising investment from governments and nonprofit organizations in adjuvant development and the rising government initiatives to launch various awareness campaigns to increase vaccination in North America along with the various product development activities taking place will eventually drive the overall market for Vaccine Adjuvants in North America during the forecast period.

Vaccine Adjuvants Market Key Players:

Some of the key market players operating in the Vaccine Adjuvants market include Dynavax Technologies, GSK plc, Croda International plc, SEPPIC, Novavax, SPI Pharma, Agenus Inc., Aurorium, Merck KGaA, Vaxine Pty Ltd., Hawaii Biotech Inc., CSL, OZ Biosciences, InvivoGen, Allergy Therapeutics, EUBIOLOGICS CO., LTD., Pacific GeneTech Limited, Riboxx GmbH, CaPtivate Pharmaceuticals LLC, Mukta Industries and others.

Recent Developmental Activities In The Vaccine Adjuvants Market:

In May 2023 Croda International Plc entered into a partnership with Amyris and Botanical Solutions Inc. firstly for biotechnology-derived squalene and secondly with BSI to develop a sustainable QS-21 vaccine adjuvant moving towards plant tissue culture-derived approach rather than the traditional method of extracting QS-21 from soap bark trees.

In August 2022, GSK Plc entered into an acquisition with Affinivax, Inc. to develop pneumococcal vaccines.

Key Takeaways From The Vaccine Adjuvants Market Report Study

Market size analysis for current Vaccine Adjuvants Market size (2023), and market forecast for 6 years (2024-2030)

Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years

Key companies dominating the global Vaccine Adjuvants market.

Various opportunities are available for the other competitors in the Vaccine Adjuvants Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current Vaccine Adjuvants market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Vaccine Adjuvants market growth in the coming future?

Target Audience Who Can Be Benefited From This Vaccine Adjuvants Market Report Study

Vaccine Adjuvants product and service providers

Research organizations and consulting companies

Vaccine Adjuvants-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in Open Angle Glaucoma (OAG)

Various end-users who want to know more about the Vaccine Adjuvants Market and the latest technological developments in the Vaccine Adjuvants Market.

Frequently Asked Questions For The Vaccine Adjuvants Market:

1. What are Vaccine Adjuvants?

Vaccine adjuvant is an ingredient used in some vaccines that helps create a stronger immune response in people receiving the vaccine.

2. What is the market for Vaccine Adjuvants?

The global vaccine adjuvants market is estimated to grow at a CAGR of 12.91% during the forecast period from 2024 to 2030.

3. What are the drivers for the global Vaccine Adjuvants market?

The Vaccine Adjuvants Market is slated to witness prosperity owing to factors such as the growing prevalence of infectious and cancer diseases. Additionally, the growing unmet vaccine market needs for certain diseases rising focus on immunization, and expanding vaccination programs across the globe are some of the other key factors that are responsible for contributing to the positive growth of the Vaccine adjuvants market during the forecast period from 2024-2030.

4. Who are the key players operating in the global Vaccine Adjuvants market?

Some of the key market players operating in the Vaccine Adjuvants market include Dynavax Technologies, GSK plc, Croda International plc, SEPPIC, Novavax, SPI Pharma, Agenus Inc., Aurorium, Merck KGaA, Vaxine Pty Ltd., Hawaii Biotech Inc., CSL, OZ Biosciences, InvivoGen, Allergy Therapeutics, EUBIOLOGICS CO., LTD., Pacific GeneTech Limited, Riboxx GmbH, CaPtivate Pharmaceuticals LLC, Mukta Industries and others.

5. Which region has the highest share in the global Vaccine Adjuvants market?

North America is expected to dominate the overall Vaccine Adjuvants Market during the forecast period from 2024 to 2030. The North America vaccine adjuvants market is experiencing growth due to several factors. Firstly, the region has a strong healthcare infrastructure and robust research and development capabilities, fostering innovation in vaccine adjuvant technologies. Additionally, rising incidences of infectious diseases and the threat of potential pandemics, such as influenza outbreaks or emerging pathogens, have prompted increased investment in vaccine development and adjuvant research. Moreover, government initiatives aimed at expanding vaccination programs and improving public health preparedness further drive market growth. Overall, these factors converge to fuel the growth of the vaccine adjuvants market in North America.